...
首页> 外文期刊>Science >The Alarmin lnterleukin-33 Drives Protective Antiviral CD8~+ T Cell Responses
【24h】

The Alarmin lnterleukin-33 Drives Protective Antiviral CD8~+ T Cell Responses

机译:Alarmin Interleukin-33驱动保护性抗病毒CD8〜+ T细胞反应

获取原文
获取原文并翻译 | 示例
           

摘要

Pathogen-associated molecular patterns decisively influence antiviral immune responses, whereas the contribution of endogenous signals of tissue damage, also known as damage-associated molecular patterns or alarmins, remains ill defined. We show that interleukin-33 (IL-33), an alarmin released from necrotic cells, is necessary for potent CD8~+ T cell (CTL) responses to replicating, prototypic RNA and DNA viruses in mice. IL-33 signaled through its receptor on activated CTLs, enhanced clonal expansion in a CTL-intrinsic fashion, determined plurifunctional effector cell differentiation, and was necessary for virus control. Moreover, recombinant IL-33 augmented vaccine-induced CTL responses. Radio-resistant cells of the splenic T cell zone produced IL-33, and efficient CTL responses required IL-33 from radio-resistant cells but not from hematopoietic cells. Thus, alarmin release by radio-resistant cells orchestrates protective antiviral CTL responses.
机译:病原体相关的分子模式决定性地影响抗病毒免疫反应,而组织损伤的内源性信号的贡献(也称为损伤相关的分子模式或警报蛋白)仍然不确定。我们表明白细胞介素33(IL-33),一种从坏死细胞释放的警报蛋白,对于小鼠中复制,原型RNA和DNA病毒的强效CD8〜+ T细胞(CTL)反应是必需的。 IL-33通过其受体激活CTL发出信号,以CTL内在的方式增强了克隆的扩增,确定了多功能效应细胞的分化,并且对于控制病毒是必需的。而且,重组IL-33增强了疫苗诱导的CTL应答。脾T细胞区的抗辐射细胞产生IL-33,而有效的CTL反应需要来自抗辐射细胞但不含造血细胞的IL-33。因此,放射抗性细胞释放的警报蛋白可以协调保护性抗病毒CTL反应。

著录项

  • 来源
    《Science》 |2012年第6071期|p.984-989|共6页
  • 作者单位

    Department of Pathology and Immunology, University of Geneva, 1 rue Michel Servet, 1211 Geneva 4, Switzerland,World Health Organization Collaborating Center for Vaccine Immunology, University of Geneva, Switzerland;

    Experimental Immunology, Department of Rheumatology and Clinical Immunology, Charite-University Medicine Berlin, Berlin, Germany,German Rheumatism Research Center (DRFZ), a Leibniz Institute, Charite'platz 1, 10117 Berlin, Germany;

    Institute for Cancer Research, Department of Pathology, University Hospital of Zurich, Schmelzbergstrasse 12, 8091 Zurich, Switzerland;

    Department of Pathology and Immunology, University of Geneva, 1 rue Michel Servet, 1211 Geneva 4, Switzerland,World Health Organization Collaborating Center for Vaccine Immunology, University of Geneva, Switzerland;

    Department of Pathology and Immunology, University of Geneva, 1 rue Michel Servet, 1211 Geneva 4, Switzerland,World Health Organization Collaborating Center for Vaccine Immunology, University of Geneva, Switzerland;

    Department of Pathology and Immunology, University of Geneva, 1 rue Michel Servet, 1211 Geneva 4, Switzerland,World Health Organization Collaborating Center for Vaccine Immunology, University of Geneva, Switzerland;

    Department of Pathology and Immunology, University of Geneva, 1 rue Michel Servet, 1211 Geneva 4, Switzerland,Division of Clinical Pathology, Geneva University Hospital, 1 rue Michel Servet, 1211 Geneva 4, Switzerland;

    Experimental Immunology, Department of Rheumatology and Clinical Immunology, Charite-University Medicine Berlin, Berlin, Germany,German Rheumatism Research Center (DRFZ), a Leibniz Institute, Charite'platz 1, 10117 Berlin, Germany,Department of Gastroenterology, Hepatology and Endocrinology, Campus Charite Mitte, Charite-University Medicine Berlin, Berlin, Germany;

    Department of Pathology and Immunology, University of Geneva, 1 rue Michel Servet, 1211 Geneva 4, Switzerland,Division of Clinical Pathology, Geneva University Hospital, 1 rue Michel Servet, 1211 Geneva 4, Switzerland;

    Institute of Molecular Medicine, St. James's Hospital, Trinity College Dublin, Dublin 8, Ireland;

    Institute for Cancer Research, Department of Pathology, University Hospital of Zurich, Schmelzbergstrasse 12, 8091 Zurich, Switzerland;

    The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, and Japan Science and Technology Agency,Precursory Research for Embryonic Science and Technology(PRESTO), 4-1-8 Hncho, Kawaguchi, Saitama 332-0012, Japan;

    Helmholtz Zentrum Munchen, Institute of Molecular Immunology and Clinical Cooperation Group Hematopoietic Cell Transplantation (CCG HCD, Marchioninistrasse 25, 81377 Munchen,Germany;

    Department of Pathology and Immunology, University of Geneva, 1 rue Michel Servet, 1211 Geneva 4, Switzerland,Division of Clinical Pathology, Geneva University Hospital, 1 rue Michel Servet, 1211 Geneva 4, Switzerland,Department of Neuropathology, University Medical Center, Georg August University, Goettingen, Germany;

    Experimental Immunology, Department of Rheumatology and Clinical Immunology, Charite-University Medicine Berlin, Berlin, Germany,German Rheumatism Research Center (DRFZ), a Leibniz Institute, Charite'platz 1, 10117 Berlin, Germany;

    Department of Pathology and Immunology, University of Geneva, 1 rue Michel Servet, 1211 Geneva 4, Switzerland,World Health Organization Collaborating Center for Vaccine Immunology, University of Geneva, Switzerland;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号